Jinxin Fertility Group
Market Cap
HK$38.2b
Last Updated
2021/01/21 10:03 UTC
Data Sources
Company Financials +
Executive Summary
Jinxin Fertility Group Limited provides assisted reproductive services (ARS) in China and the United States. More Details
Rewards
Risk Analysis
No risks detected for 1951 from our risk checks.
Snowflake Analysis
Flawless balance sheet with proven track record.
Share Price & News
How has Jinxin Fertility Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1951 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 1951's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
10.5%
1951
7.9%
HK Healthcare
5.7%
HK Market
1 Year Return
34.6%
1951
-11.4%
HK Healthcare
14.3%
HK Market
Return vs Industry: 1951 exceeded the Hong Kong Healthcare industry which returned -11.4% over the past year.
Return vs Market: 1951 exceeded the Hong Kong Market which returned 14.3% over the past year.
Shareholder returns
| 1951 | Industry | Market | |
|---|---|---|---|
| 7 Day | 10.5% | 7.9% | 5.7% |
| 30 Day | 1.3% | 7.6% | 13.6% |
| 90 Day | 63.4% | 23.1% | 19.6% |
| 1 Year | 35.3%34.6% | -9.1%-11.4% | 18.9%14.3% |
| 3 Year | n/a | -40.8%-44.6% | -2.9%-13.1% |
| 5 Year | n/a | -20.5%-28.4% | 70.9%42.2% |
Long-Term Price Volatility Vs. Market
How volatile is Jinxin Fertility Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
We're Watching These Trends At Jinxin Fertility Group (HKG:1951)3 weeks ago | Simply Wall St
Jinxin Fertility Group (HKG:1951) Is Growing Earnings But Are They A Good Guide?Valuation
Is Jinxin Fertility Group undervalued compared to its fair value and its price relative to the market?
10.2%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1951 (HK$15.34) is trading below our estimate of fair value (HK$17.09)
Significantly Below Fair Value: 1951 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 1951 is poor value based on its PE Ratio (86.4x) compared to the HK Healthcare industry average (21.6x).
PE vs Market: 1951 is poor value based on its PE Ratio (86.4x) compared to the Hong Kong market (11.9x).
Price to Earnings Growth Ratio
PEG Ratio: 1951 is poor value based on its PEG Ratio (3.7x)
Price to Book Ratio
PB vs Industry: 1951 is overvalued based on its PB Ratio (4.1x) compared to the HK Healthcare industry average (1.5x).
Next Steps
Future Growth
How is Jinxin Fertility Group forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
23.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1951's forecast earnings growth (23.4% per year) is above the savings rate (1.5%).
Earnings vs Market: 1951's earnings (23.4% per year) are forecast to grow faster than the Hong Kong market (21.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1951's revenue (18.9% per year) is forecast to grow faster than the Hong Kong market (14.2% per year).
High Growth Revenue: 1951's revenue (18.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1951's Return on Equity is forecast to be low in 3 years time (9.5%).
Next Steps
Past Performance
How has Jinxin Fertility Group performed over the past 5 years?
38.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1951 has high quality earnings.
Growing Profit Margin: 1951's current net profit margins (24.2%) are higher than last year (20.7%).
Past Earnings Growth Analysis
Earnings Trend: 1951's earnings have grown significantly by 38.6% per year over the past 5 years.
Accelerating Growth: 1951's earnings growth over the past year (31.7%) is below its 5-year average (38.6% per year).
Earnings vs Industry: 1951 earnings growth over the past year (31.7%) exceeded the Healthcare industry -9.1%.
Return on Equity
High ROE: 1951's Return on Equity (4.8%) is considered low.
Next Steps
Financial Health
How is Jinxin Fertility Group's financial position?
Financial Position Analysis
Short Term Liabilities: 1951's short term assets (CN¥3.4B) exceed its short term liabilities (CN¥610.7M).
Long Term Liabilities: 1951's short term assets (CN¥3.4B) exceed its long term liabilities (CN¥902.6M).
Debt to Equity History and Analysis
Debt Level: 1951 is debt free.
Reducing Debt: 1951 has not had any debt for past 5 years.
Debt Coverage: 1951 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 1951 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Jinxin Fertility Group current dividend yield, its reliability and sustainability?
0.44%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1951's dividend (0.44%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.04%).
High Dividend: 1951's dividend (0.44%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.52%).
Stability and Growth of Payments
Stable Dividend: 1951 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.
Growing Dividend: 1951 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 1951 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1951's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.0yrs
Average management tenure
CEO
Ying Zhong (61 yo)
3.5yrs
Tenure
Mr. Ying Zhong has been an Executive Director and Chief Executive Officer of Jinxin Fertility Group Limited since August 17, 2018 and July 4, 2017, respectively. He joined Jinxin Fertility Group in March 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 3.5yrs | no data | no data | |
| Co-CEO & Executive Director | 2.67yrs | no data | no data | |
| Vice Chairman & Executive Director | 0.58yr | no data | no data | |
| Chief Financial Officer | 2.25yrs | no data | no data | |
| Chief Compliance Officer | 2yrs | no data | no data | |
| Executive Director | 2.08yrs | no data | no data | |
| Chief Scientific Officer | 2.33yrs | no data | no data | |
| Senior Vice President | 2.33yrs | no data | no data | |
| Joint Company Secretary | 2yrs | no data | no data | |
| Joint Company Secretary | 2yrs | no data | no data |
2.0yrs
Average Tenure
48yo
Average Age
Experienced Management: 1951's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 3.5yrs | no data | no data | |
| Co-CEO & Executive Director | 2.67yrs | no data | no data | |
| Vice Chairman & Executive Director | 0.58yr | no data | no data | |
| Executive Director | 2.08yrs | no data | no data | |
| Non-Executive Director | 2.08yrs | no data | no data | |
| Independent Non Executive Director | 1.58yrs | no data | no data | |
| Independent Non-Executive Director | 1.58yrs | no data | no data | |
| Chairman | 2.08yrs | no data | no data | |
| Independent Non-Executive Director | 1.58yrs | no data | no data | |
| Non-Executive Director | 2.08yrs | no data | no data | |
| Independent Non-Executive Director | 1.58yrs | no data | no data |
2.1yrs
Average Tenure
49yo
Average Age
Experienced Board: 1951's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Jinxin Fertility Group Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Jinxin Fertility Group Limited
- Ticker: 1951
- Exchange: SEHK
- Founded: 2003
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: HK$38.210b
- Shares outstanding: 2.43b
- Website: https://www.jxr-fertility.com
Number of Employees
Location
- Jinxin Fertility Group Limited
- No. 301
- North Jingsha Road
- Chengdu
- Sichuan Province
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 1951 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Ordinary Shares | HK | HKD | Jun 2019 |
| 3NX | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jun 2019 |
| 1951 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Yes | Ordinary Shares | HK | HKD | Jun 2019 |
| 1951 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Ordinary Shares | HK | HKD | Jun 2019 |
Biography
Jinxin Fertility Group Limited provides assisted reproductive services (ARS) in China and the United States. The company primarily offers its patients with two treatment solutions, including artificial ins...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/21 10:03 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.